Concentrations plasmatiques des glutathions et leurs corrélations avec les caractéristiques cliniques et thérapeutiques des patients atteints de schizophrénie |
| |
| Authors: | M Raffa I Bel Hadj Youssef L Ben Othman C Fendri A Mechri |
| |
| Institution: | 1. Department of psychiatry, Pitié-Salpêtrière Hospital, AP–HP, Paris, France.;2. Control-Interoception-Attention team, Paris Brain Institute, Sorbonne University, Paris, France.;1. Service Pharmacie, AP-HP, GH Saint-Louis–Lariboisière–F. Widal, 75475 Paris cedex 10, France;2. Iserm U1144 optimisation thérapeutique en neuropsychopharmacologie, université Paris Descartes, université Paris Diderot, université Sorbonne Paris Cité, Paris, France;3. Département de Psychiatrie et de Médecine Addictologique, AP-HP, GH Saint-Louis–Lariboisière–F. Widal, 75475 Paris cedex 10, France;1. Faculté de biologie et de médecine, université de Lausanne, rue du Bugnon 21, 1005 Lausanne, Suisse;2. Institut humanités, sciences et société, université de Paris, 5, rue Thomas-Mann, 75013 Paris, France;3. Fondation Agalma, campus biotech, chemin des Mines 9, 1202 Genève, Suisse;1. EA 3279 : CEReSS – Centre d’étude et de recherche sur les services de santé et la qualité de vie, faculté de médecine – Secteur Timone, hôpitaux universitaires de Marseille, Marseille université, Assistance publique des Hôpitaux de Marseille, Marseille, France;2. Nightingale Hospitals-Paris, clinique du Château de Garches, 11bis, rue de la Porte-Jaune, 92380 Garches, France;3. Service hospitalo-universitaire, centre hospitalier Sainte-Anne, 1, rue Cabanis, 75014 Paris, France;1. CPOA, hôpital Sainte-Anne, GHU Paris Psychiatrie & Neurosciences, 1, rue Cabanis, 75014 Paris, France;2. Pôle 75G28, hôpital Maison-Blanche, GHU Paris Psychiatrie & Neurosciences, Paris, France;3. 46, boulevard de l’hôpital, 75013 Paris, France;1. Centre hospitalier Sud francilien, 40, avenue Serge-Dassault, 91100 Corbeil-Essonnes, France;2. SHU Fondation vallée, 7, rue Benserade, 94257 Gentilly cedex, France;3. Hôpital universitaire Robert-Debré, 48, boulevard Sérurier, 75019 Paris, France;4. CHU de la Pitié-Salpêtrière, 7–83, boulevard de l’Hôpital, 75013 Paris, France |
| |
| Abstract: | IntroductionAltered glutathione systems (GSH) are suggested to participate in the pathophysiology of schizophrenia. The purpose of this study was to determine the plasmatic glutathione levels of patients with schizophrenia compared to healthy controls and to examine their relationships with clinical and therapeutic features.MethodsIt was a case-control study carried out on 100 patients with schizophrenia according to DSM-IV-TR criteria and 95 healthy controls. All patients were assessed by Clinical Global Impressions-severity (CGI-severity) and Global Assessment of Functioning (EGF). Most of the patients (55%) were under first-generation antipsychotics. Plasmatic glutathione levels (total glutathione GSHt, reduced glutathione GSHr, oxidized glutathione GSSG) were determined by spectrophotometry.ResultsThe levels of GSHt and GSHr were significantly decreased in schizophrenic patients in comparison with the healthy controls. These reductions were noted to be more pronounced in the untreated patients. No correlation was observed between the GSH levels and the clinical subtypes of schizophrenia and EGF scores. Depending on the therapeutic status, there were no significant differences in the GSH levels. In addition, there was no correlation between the GSH levels and the daily dosage of the antipsychotic treatment.ConclusionOur results suggest that the observed changes are related to the physiopathology of schizophrenia rather than to the presence of neuroleptic treatment. These results provide support for further studies of the possible role of antioxidants as neuroprotective therapeutic strategies. |
| |
| Keywords: | Schizophrenia Oxidative stress Glutathione Case control study |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
